Innate Therapeutics initiates phase II testing of MIS416
Posted: Mon Oct 11, 2010 5:48 am
Innate Therapeutics initiates phase II testing of MIS416 in patients with Progressive MS
Innate Therapeutics today announced that the company has begun treating patients in a Phase 2a clinical study of its lead molecule, MIS416, in patients with progressive multiple sclerosis (MS).
“MIS416 is believed to work through a combination of mechanisms involving the down regulation of chronic inflammation, reduction of autoimmune factors, and the repair of damaged tissue,” said Simon Wilkinson, Innate Therapeutics chief executive officer....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
Innate Therapeutics today announced that the company has begun treating patients in a Phase 2a clinical study of its lead molecule, MIS416, in patients with progressive multiple sclerosis (MS).
“MIS416 is believed to work through a combination of mechanisms involving the down regulation of chronic inflammation, reduction of autoimmune factors, and the repair of damaged tissue,” said Simon Wilkinson, Innate Therapeutics chief executive officer....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397